PAI
STOK icon

Palo Alto Investors’s Stoke Therapeutics STOK Stock Holding History

Palo Alto Investors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76M Buy
84,631
+12,609
+18% +$414K 0.42% 32
2025
Q4 		$2.29M Sell
72,022
-33,405
-32% -$1M 0.32% 35
2025
Q3 		$2.48M Sell
105,427
-20,434
-16% -$350K 0.46% 33
2025
Q2 		$1.43M Hold
125,861
– – 0.3% 35
2025
Q1 		$837K Hold
125,861
– – 0.16% 37
2024
Q4 		$1.39M Hold
125,861
– – 0.22% 34
2024
Q3 		$1.55M Hold
125,861
– – 0.2% 33
2024
Q2 		$1.7M Hold
125,861
– – 0.2% 32
2024
Q1 		$1.7M Buy
+125,861
New +$763K 0.19% 31

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Palo Alto Investors's STOK Position: Q1 2026 in Review

Palo Alto Investors increased its Stoke Therapeutics (STOK) stake by 18% in Q1 2026, buying an estimated $414K and bringing the position to 84,631 shares worth $2.76M. The position accounts for 0.42% of the portfolio, ranked #32.

Palo Alto Investors first reported a position in STOK in Q1 2024 and has held it in 9 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Palo Alto Investors held 84,631 shares of Stoke Therapeutics worth $2.76M as of Q1 2026.
  • Palo Alto Investors bought 12,609 Stoke Therapeutics shares in Q1 2026, an estimated $414K.
  • Stoke Therapeutics made up 0.42% of Palo Alto Investors's portfolio in Q1 2026, its #32 holding.
  • Palo Alto Investors first reported a position in Stoke Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.